Improving the Dosing Schedules of Targeted Anticancer Agents

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Cancer treatment optimization involves modifying dosing regimens of approved drugs.
• Off-label practices for therapeutic and economic reasons are increasingly being re-evaluated by regulatory agencies.
• Patient quality of life and treatment convenience, including 'time toxicity,' are key considerations.

Purpose of the Study:

• To explore the multifaceted optimization of anticancer drug dosing.
• To examine the benefits/risks balance, treatment convenience, and financial impact of dose adjustments.
• To illustrate dose reassessments using examples of targeted therapies.

Main Methods:

• Review of academic experiments in drug regimen modification.
• Analysis of off-label practices and regulatory reappraisal.
• Case examples of dose reassessments for molecularly targeted agents approved since 1997.

Main Results:

• Suboptimal or overdosed regimens exist for some molecularly targeted agents, often due to reliance on the maximum tolerated dose concept.
• There's a noted lack of comparative effective dose trials prior to drug approval.
• Dosing regimens for newly approved agents are evolving towards improved convenience and tolerability.

Conclusions:

• Optimizing anticancer drug dosing offers significant benefits for patients and healthcare professionals.
• Future dosing strategies aim for more convenient and better-tolerated treatments.
• The economic implications of optimized dosing remain an unaddressed challenge.